Date:3/14/2011

sistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.  In December of 2010, we acquired another CLIA certified laboratory in New Haven, Connecticut which specializes in genetic disorders associated with cardiomyopathies and channelopathies.  We believe there is a significant opportunity for us to continue growing the demand for molecular-based testing by leveraging our technologies, experience and expertise in biomarker analysis. In addition, we continue to seek out and evaluate new technologies and new laboratory tests which will further extend our offerings in our Molecular Diagnostics Laboratory and our Pharmacogenomics Services Lab.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Se
'/>"/>

SOURCE Transgenomic, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Transgenomic Reports Fourth Quarter Financial Results
2. Transgenomic Announces Closing of the Acquisition of Clinical Datas Diagnostic Business and the Closing of a $6 Million Financing
3. Transgenomic Expands Distribution of SURVEYOR® Scan K-RAS Mutation Detection Kit With CE IVD Mark
4. Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference
5. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
6. Transgenomic Reports Fourth Quarter Financial Results
7. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
8. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
9. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
10. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
11. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute